Home  /  Resource Library  /  Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Results of a phase II study investigating daratumumab for patients with relapsed Extranodal Natural Killer T-cell Lymphoma.